History

The International Institute for Drug Development (ID2) was established in Brussels (Belgium) in 1991 by Marc Buyse  ScD. With over 25 years of experience, IDDI is a valuable partner in the design, conduct and analysis in clinical research through optimal study design, innovative statistical methodology and state-of-the-art integrated web systems that help achieve time savings and cost-effective clinical trial processes.

BRUSSELS, BELGIUM
BRUSSELS, BELGIUM
1991

The International Institute for Drug Development (ID2) was established in Brussels (Belgium) in 1991 by Marc Buyse  ScD.

PARIS, FRANCE
PARIS, FRANCE
1996

The company expanded its client base in France and opened an office in Paris to ensure proximity to its French clients.

CAMBRIDGE, MA, USA
CAMBRIDGE, MA, USA
2001

The company was renamed IDDI, International Drug Development Institute. An office was opened in Cambridge, Massachusetts, to offer advanced web-based services for clinical research supported by a dedicated help desk to cover the American time zones. Business development and Finance still operate out of Cambridge, MA to serve IDDI’s American clients.

EUROPEAN TEAM
2004

Closed Paris office and consolidated European team in Belgium.

LOUVAIN-LA-NEUVE, BELGIUM
LOUVAIN-LA-NEUVE, BELGIUM
2006

Moved headquarter to Louvain-la-Neuve.

HOUSTON, TX, USA
HOUSTON, TX, USA
2011

IDDI opened a new office in Houston Texas. Operational team in the US.

CLUEPOINTS
CLUEPOINTS
2012

Creation of a new branch, CluePoints, dedicated to Central Statistical Monitoring applied to clinical trials.

NEW LOGO AND STRATEGY
NEW LOGO AND STRATEGY
2013

Revamp of IDDI Logo and strategy based on the three pillars of the company: PEOPLE, METHODOLOGY and TECHNOLOGY.

RALEIGH, NC, USA
RALEIGH, NC, USA
2014

IDDI opens a new office in Raleigh in October 2014 and provides Data Management, Biostatistics and Project Management staff to serve US based clients.

IDDI 25 YEAR ANNIVERSARY
IDDI 25 YEAR ANNIVERSARY
2016
IDDI Shareholding Evolutions
IDDI Shareholding Evolutions
2017

IDDI extends its shareholding. SRIW (Société Régionale d’Investissement de Wallonie) takes 20% equity stake and IDDI management’s stake increases to 30%. This evolution is a major milestone for the company perennity and development.

TODAY
TODAY
2017

With over 26 years of experience, IDDI is a valuable partner in the design, conduct and analysis in clinical research through optimal design, innovative statistical methodology and state-of-the-art integrated web systems that help achieve time savings and cost-effective clinical trial processes.